{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(5)"],"submitter":["Frustaci AM"],"pubmed_abstract":["Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially"],"journal":["Cancers"],"pagination":["1504"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10000925"],"repository":["biostudies-literature"],"pubmed_title":["Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities."],"pmcid":["PMC10000925"],"pubmed_authors":["Tedeschi A","Montillo M","Cairoli R","Frustaci AM","Deodato M","Zamprogna G"],"additional_accession":[]},"is_claimable":false,"name":"Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.","description":"Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T03:41:42.59Z","creation":"2025-04-04T03:41:42.59Z"},"accession":"S-EPMC10000925","cross_references":{"pubmed":["36900295"],"doi":["10.3390/cancers15051504"]}}